Novo Nordisk’s Denecimig Shows Strong Phase 3 Hemophilia Data
PLAINSBORO, New Jersey, USA / BAGSVÆRD, Denmark, July 11, 2026 Novo Nordisk has announced positive long-term Phase 3 results...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PLAINSBORO, New Jersey, USA / BAGSVÆRD, Denmark, July 11, 2026 Novo Nordisk has announced positive long-term Phase 3 results...
SILVER SPRING, Maryland, July 10, 2026 The U.S. Food and Drug Administration (FDA) has proposed a new rule designed...
MUMBAI, India, July 6, 2026 Lupin Limited, one of the world’s leading pharmaceutical companies, has been recognized among TIME...
RANCHO CORDOVA, California, USA | March 24, 2026 In a significant move to advance sustainable pharmaceutical manufacturing, SK pharmteco...
Houston, Texas – September 23, 2025 — Eli Lilly and Company (NYSE: LLY) will invest $6.5 billion to build...
